상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Promoter methylation status of VEGF receptor genes-a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting vegf-targeted drugs in cancer cells

Authors 

J KimJ HwangH JeongH J SongJ ShinG HurYoung Woo ParkS H Lee

Publisher 

Landes Bioscience

Issue Date 

2012

Citation 

Epigenetics, vol. 7, no. 2, pp. 191-200

Keywords 

Epigenetic changeFlt1KDRPromoter hypermethylationVascular endothelial growth factor (VEGF)VEGF receptor (VEGFR)VEGF-specific antibodyVEGF-specific tyrosine kinase inhibitorVEGF-targeted drugVEGFR2-specific antibody --------------------------------------------------------------------------------

Abstract 

We evaluated whether the inhibitory effects of vascular endothelial growth factor (VEGF)-targeted drugs on the proliferation of cancer cells differed according to VEGF receptor (VEGFR) genes, Flt1 and KDR, promoter methylation status. Five hyper-VEGFR-methylation and six no-VEGFR-methylation cancer cells were used for the present study, together with human umbilical endothelial cells (HUVECs) as a control. No-VEGFR-methylation cancer cells showed higher expression of Flt1 and KDR than hyper-VEGFR-methylation cancer cells. Hyper-VEGFR-methylation cancer cells only showed increased expression and protein levels of Flt1 and KDR after treatment with the de methylase 5-aza-2'-deoxycytidine. Two drugs (a VEGF-specific-antibody, bevacizumab and a KDR-specific-antibody) targeting extracellular VEGF-VEGFR signaling and two VEGF-specific-tyrosine kinase inhibitors (PTK/ZK and sunitinib) targeting intracellular VEGFR signaling were used in the cell proliferation assay. HUVECs showed dose- and time-dependent proliferation decrease with all tested drugs over a 72 h incubation period. No- or hyper-VEGFR-methylation cancer cells showed no significant proliferation diferences after treatment with VEGF-specific-antibody or VEGFR2-specific-antibody. After PTK/ZK or sunitinib treatment, no-VEGFR-methylation cancer cells showed dose- or time-dependent decreases in proliferation. Hyper-VEGFR-methylation cancer cells also showed proliferation inhibition by VEGF-specific-tyrosine kinase inhibitors after de methylation of Flt1 and KDR. Proliferation inhibition synergistically increased after combination of de methylation with PTK/ZK in hyper-VEGF-methylation cancer cells. We observed that intracellular targeting of VEGF-VEGFR signaling could be more effective than extracellular targeting of the pathway in the suppression of proliferation of some cancer cells. In particular, the efficacy of intracellular targeting of VEGF-specific-tyrosine kinase inhibitors might be influenced by the epigenetic alteration of VEGFRs.

ISSN 

1559-2294

Link 

http://dx.doi.org/10.4161/epi.7.2.18973

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-05-02


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)